ArticleThe American journal of tropical medicine and hygiene2025
Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in a Rural Community in Western Kenya during the First 24 Months of the Coronavirus Disease 2019 Pandemic.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Seroreactivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens was commonly reported in African settings during the early stages of the coronavirus disease 2019 pandemic. Severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (nAbs) are not only correlated with functional protection from disease but also are highly specific responses to the virus. These responses were used to investigate the evolution of virus exposure in a community-based, longitudinal cohort of 504 individuals in rural Western Kenya. Eluates from dried blood spots collected every 3 months from January 2020 to September 2021 were tested for nAbs using a commercial kit. Only 10 individuals developed SARS-CoV-2 nAbs, all of which were clustered in December 2020 (wildtype virus) and September 2021 (delta variant). After seroconversion, all patients seroreverted within 2 months. Despite reports of widespread viral exposure in Western Kenya from 2020 to 2021, the paucity of nAbs highlights the limited natural immunity present when vaccines became available in late 2021 in Kenya.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.